Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Daniele S. C. Ramsay has a total of 57 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Risk factors for surgical site infections after spinal surgery: a systematic review and meta-analysis

    by Sophie-Liliane Rosenke, Myles Kisekka, Hiend Darweesh, Brawin Kajenthra, Jake Hewitt, Daniele Ramsay, Hariharan Subbiah Ponniah, Dragan Jankovic, Daniel Scurtu, Darius Kalasauskas, et al.

    Purpose: Surgical site infections (SSIs) are a serious complication of spinal surgery, leading to prolonged hospital stays, increased healthcare costs, and worse patient outcomes. This review aimed to synthesise current evidence on modifiable risk factors for SSIs in spinal surgery to identify targets for intervention, perioperative optimisation, and improve patient care. Methodology: A systematic search of MEDLINE, Embase, Scopus, Academic Search Ultimate, and CINAHL was conducted on 10 March 2024. Risk of bias was assessed using the Newcastle-Ottawa Scale, ROBINS-E, and the Oxford Centre for Evidence-Based Medicine: Levels of Evidence. A random-effects meta-analysis generated pooled odds ratios (ORs) with 95% confidence intervals (CI). Heterogeneity was assessed using I², Cochran’s Q, and associated p-values. Sensitivity and influence analyses evaluated the robustness. Results: Forty-four studies were included, comprising 637,032 patients and 9,745 SSIs. Modifiable risk factors associated with increased SSI risk included body mass index, diabetes mellitus (including insulin-dependent), smoking, low preoperative haematocrit (< 33–39%), and chronic steroid use. Subcutaneous fat thickness > 30 mm and operative time > 2 h were also considered partially modifiable. Intraoperative vancomycin powder significantly reduced SSI risk. Non-modifiable risk factors included (American Society of Anaesthesiologists) ASA ≥ 3, female sex, coronary artery disease, revision surgery and procedures involving ≥ 3 vertebral levels. Age, alcohol use, albumin levels, instrumentation and blood transfusion were not significantly associated. High heterogeneity was noted for several variables, particularly BMI and diabetes. Conclusion: Several modifiable risk factors for SSIs were identified. Intraoperative vancomycin powder showed a protective effect. These findings offer perioperative strategies including glycaemic control, smoking cessation, anaemia management, and steroid dose adjustments to reduce SSI incidence and improve outcomes.


  • Open Access

    Neuroanatomy Education Access by Country Income Level: A Mixed-Methods Analysis

    by Daniele S.C. Ramsay, Benjamin J. Nicholls, Natasha Dixon, Marimo Rossiter, Lana Al-Nusair, Gideon Adegboyega, Kevin Tsang, Nigel Mendoza


  • Open Access

    Auditory hallucinations induced by atorvastatin and exacerbated by cefalexin: a rare case report

    by Daniele S. C. Ramsay, Harvey Stevenson, Waseem Jerjes

    Background: Auditory hallucinations, commonly associated with psychiatric conditions such as schizophrenia, can arise as side effects to certain medications. Several drug classes are commonly implicated in the causation of hallucinations, such as anticholinergics. Medication associated with disruption of steroid production may lead to neuropsychiatric disruption. One such drug class, statins, may also have psychiatric sequelae. Wide prescribing of common medication such as atorvastatin, allows the unveiling of uncommon medication-related adverse events. Case Description: We detail a unique case-report of a 60-year-old man experiencing auditory hallucinations post-initiation of atorvastatin. The content of the hallucinations consisted of voices of deceased family members. These were frequently accompanied by predominantly frontal headaches. Subsequently, during the treatment of a chest infection utilizing cefalexin, the auditory hallucinations intensified in clarity and increased in frequency. Despite initial concerns related to a family history of meningiomas, magnetic resonance imaging ruled out structural abnormalities. Comprehensive viral screening excluded infectious as the causative factor and there were no signs of concurrent delirium. Following termination of the course of cefalexin, the hallucinations reduced in intensity. The cessation of atorvastatin led to the resolution of hallucinations. Conclusions: This case emphasizes the importance of drug history evaluation in neuropsychiatric presentations and prompts further exploration into the neuropsychiatric effects of commonly prescribed drugs.


  • Open Access

    Update on Neoadjuvant and Adjuvant BRAF Inhibitors in Papillary Craniopharyngioma: A Systematic Review

    by Giulia Cossu, Daniele S. C. Ramsay, Roy T. Daniel, Ahmed El Cadhi, Luc Kerherve, Edouard Morlaix, Sayda A. Houidi, Clément Millot-Piccoli, Renan Chapon, Tuan Le Van, et al.

    Background/Objectives: The recent discovery of BRAF mutation in papillary craniopharyngiomas opened new avenues for targeted therapies to control tumour growth, decreasing the need for invasive treatments and relative complications. The aim of this systematic review was to summarize the recent scientific data dealing with the use of targeted therapies in papillary craniopharyngiomas, as adjuvant and neoadjuvant treatments. Methods: The PRISMA guidelines were followed with searches performed in Scopus, MEDLINE, and Embase, following a dedicated PICO approach. Results: We included 21 pertinent studies encompassing 53 patients: 26 patients received BRAF inhibitors (BRAFi) as adjuvant treatment, while 25 received them as neoadjuvant treatment. In the adjuvant setting, BRAFi were used to treat recurrent tumours after surgery or adjuvant radiation therapy. The most common regimen combined dabrafenib (BRAFi) with trametinib (MEK1 and 2 inhibitor) in 81% of cases. The mean treatment length was 8.8 months (range 1.6 to 28 months) and 32% were continuing BRAFi. A reduction of tumour volume variable from 24% to 100% was observed at cerebral MRI during treatment and volumetric reduction ≥80% was described in 64% of cases. Once the treatment was stopped, adjuvant treatments were performed to stabilize patients in remission in 11 cases (65%) or when a progression was detected in three cases (12%). In four cases no further therapies were administered (16%). Mean follow-up after the end of targeted therapy was 17.1 months. As neoadjuvant regimen, 36% of patients were treated with dabrafenib and trametinib with a near complete radiological response in all the cases with a mean treatment of 5.7 months. The neoadjuvant use of verumafenib (BRAFi) and cometinib (MEK1 inhibitor) induced a near complete response in 15 patients (94%), with a median volumetric reduction between 85% and 91%. Ten patients did not receive further treatments. Side effects varied among studies. The optimal timing, sequencing, and duration of treatment of these new therapies should be established. Moreover, questions remain about the choice of specific BRAF/MEK inhibitors, the optimal protocol of treatment, and the strategies for managing adverse events. Conclusions: Treatment is shifting to a wider multidisciplinary management, where a key role is played by targeted therapies, to improve outcomes and quality of life for patients with BRAF-mutated craniopharyngiomas. Future, larger comparative trials will optimize their protocol of use and integration into multimodal strategies of treatment.


  • Open Access

    Artificial Intelligence for Prediction of Shunt Response in Idiopathic Normal Pressure Hydrocephalus: A Systematic Review

    by Rafael Tiza Fernandes, Filipe Wolff Fernandes, Mrinmoy Kundu, Daniele S.C. Ramsay, Ahmed Salih, Srikar N. Namireddy, Dragan Jankovic, Darius Kalasauskas, Malte Ottenhausen, Andreas Kramer, et al.


  • Open Access

    Enhancing Oral Cancer Detection: A Systematic Review of the Diagnostic Accuracy and Future Integration of Optical Coherence Tomography with Artificial Intelligence

    by Waseem Jerjes, Harvey Stevenson, Daniele Ramsay, Zaid Hamdoon

    Introduction: Optical Coherence Tomography (OCT) has emerged as an important imaging modality in non-invasive diagnosis for oral cancer and can provide real-time visualisation of tissue morphology with the required high resolution. This systematic review aims to assess the diagnostic accuracy of OCT in the detection of oral cancers, and to explore the potential integration of OCT with artificial intelligence (AI) and other imaging techniques to enhance diagnostic precision and clinical outcomes in oral healthcare. Methods: A systematic literature search was conducted across PubMed, Embase, Scopus, Google Scholar, Cochrane Central Register, and Web of Science from inception until August 2024. Studies were included if they employed OCT for oral cancer detection, reported diagnostic outcomes, such as sensitivity and specificity, and were conducted on human subjects. Data extraction and quality assessment were performed independently by two reviewers. The synthesis highlights advancements in OCT technology, including AI-enhanced interpretations. Results: A total of 9 studies met the inclusion criteria, encompassing a total of 860 events (cancer detections). The studies spanned from 2008 to 2022 and utilised various OCT techniques, including clinician-based, algorithm-based, and AI-driven interpretations. The findings indicate OCT’s high diagnostic accuracy, with sensitivity ranging from 75% to 100% and specificity from 71% to 100%. AI-augmented OCT interpretations demonstrated the highest accuracy, emphasising OCT’s potential in early cancer detection and precision in guiding surgical interventions. Conclusions: OCT could play a very prominent role as a new diagnostic tool for oral cancer, with very high sensitivity and specificity. Future research pointed towards integrating OCT with other imaging methods and AI systems in providing better accuracy of diagnoses, plus more clinical usability. Further development and validation with large-scale multicentre trials is imperative for the realisation of this potential in changing the way we practice oral healthcare.


  • Open Access

    Examining Introduction of E-consent in the Neurosurgical Caseload: Understanding the Barriers to Implementation

    by Daniele S.C. Ramsay, Virensinh Rathod, Sami Rashed, Sohani Dassanayake, Santhosh Thavarajasingam, Nigel Mendoza, Ali Rezaei Haddad


  • Open Access

    Mental Health Polypharmacy in “Non-Coded” Primary Care Patients: The Effect of Deprescribing

    by Waseem Jerjes, Daniele Ramsay, Harvey Stevenson, Karima Lalji

    Background: Mental health (MH) polypharmacy, defined as prescribing multiple mental health medications for the same condition, presents significant challenges in clinical practice. With varying prevalence rates and an increasing trend, particularly in the UK, this deprescribing prospective quality improvement project aimed to address the complexities and risks associated with MH polypharmacy. Patients and Methods: A large primary care centre in London was selected for this project. Electronic records of 667 patients (non-coded in mental health lists) were analysed as a result of the absence of a Systematised Nomenclature of Medicine Clinical Terms (SNOMED CT) for mental health. Seventy-two non-coded patients exhibiting “same-class” as well as “adjunctive” and “augmentation” polypharmacy were identified. Their demographic and health data, including MH diagnoses, physical status, and lifestyle habits, were evaluated. This deprescribing prospective project included 68 patients and employed a model inspired by the Plan–Do–Study–Act (PDSA) cycle, focusing on reducing psychotropic, adjunctive, and augmentative medications while monitoring mental health control through face-to-face consultations using the Patient Health Questionnaire-9 (PHQ-9) and Generalised Anxiety Disorder Assessment-7 (GAD-7) scores, alongside physical health parameters. Results: The project revealed a significant decrease in the average number of psychotropic and adjunct medications from initial consultations to the end of the 18-month period. Additionally, a marked reduction in reported side effects and drug interactions was observed. Improvements in mental health control, as evidenced by PHQ-9 and GAD-7 scores, were noted. Physical health parameters, including BMI, blood pressure, heart rate, HbA1c, and cholesterol levels, also showed significant improvements. Educational initiatives for patients and clinicians were successfully implemented, contributing to these positive outcomes. Discussion: The project faced challenges like balancing medication reduction with mental health stability, patient apprehension, and the absence of standardised protocols. However, the successful reduction in medication numbers and the improvement in health outcomes highlight the effectiveness of the model. This project underscores the necessity of a tailored approach to MH polypharmacy, emphasising continuous education, clinical titration, and adherence to guidelines. Future research is needed to develop clear guidelines for medication combination in mental health care and to understand the long-term effects of polypharmacy in mental health populations. Conclusions: This project demonstrates the potential for significant improvements in the management of MH polypharmacy. By carefully managing medication reductions and employing a comprehensive care approach, including patient education and clinician training, the project achieved improvements in both mental and physical health outcomes. These findings suggest a promising direction for future practices in MH polypharmacy management.


  • Open Access

    From Basic Mechanisms to Clinical Research: Photodynamic Therapy Applications in Head and Neck Malignancies and Vascular Anomalies

    by Daniele Ramsay, Harvey Stevenson, Waseem Jerjes

    Head and neck cancers are largely squamous cell carcinomas derived from the epithelial lining of the structures in the region, and are often classified anatomically into oral, oropharyngeal, nasopharyngeal and laryngeal carcinomas. The region’s component structures serve complex and intricate functions, such as speaking, swallowing and breathing, which are often compromised by these neoplasms. Such lesions may also cause disfigurement, leading to distressing social and psychological issues. Conventional treatments of these neoplasms usually involve surgical intervention with or without chemoradiotherapy. These have shown to be efficacious; however, they can also cause damage to healthy as well as diseased tissue, exacerbating the aforementioned problems. Access to a given region to deliver the treatments is also often a problem, due to the complex anatomical structures involved. The use of photodynamic therapy in the head and neck region has been established for about two decades. In this review, we looked at the basic mechanisms of this intervention, examined its use in common head and neck malignancies and vascular anomalies, and reported on the most recent clinical studies. We further included a clinical guide which can help replicate the use of this technology by any unit. Based on this review, photodynamic therapy has been shown to be efficacious in the treatment of head and neck malignancies and vascular tumours. This therapy can be targeted to the diseased tissue and causes no damage to underlying structures. Recent studies have shown this therapy to be as effective as conventional therapies, without causing major adverse effects.